Literature DB >> 7577804

Both CD28 ligands CD80 (B7-1) and CD86 (B7-2) activate phosphatidylinositol 3-kinase, and wortmannin reveals heterogeneity in the regulation of T cell IL-2 secretion.

Y Ueda1, B L Levine, M L Huang, G J Freeman, L M Nadler, C H June, S G Ward.   

Abstract

In this report, the co-stimulatory signals provided by CD80 (B7-1) or CD86 (B7-2) were compared to CD28 ligation by mAb. We demonstrate that while both anti-CD3 and anti-CD28 antibodies induced activation of phosphoinositide (PI) 3-kinase, the kinetics of activation differed. Anti-CD28 produced a sustained activation of PI 3-kinase while anti-CD3 induced activation was transient. Both B7-1 and B7-2 could induce prolonged activation of PI 3-kinase. The co-stimulatory effects of B7-1 and B7-2 were dependent on CD28 cross-linking, based on complete inhibition of PI 3-kinase activation by CD28 antibody Fab fragments. While Jurkat T cells co-stimulated with anti-CD3 and B7-1 or B7-2 secreted high levels of IL-2, there were distinct effects of anti-CD28 mAb and B7-1 or B7-2 on IL-2 secretion in conjunction with protein kinase C activation. To assess functional effects of CD28 ligation, pharmacologic inhibitors of PI 3-kinase were evaluated. In Jurkat cells, efficient inhibition of PI 3-kinase activation after B7-2 stimulation was achieved using wortmannin; however, we observed a surprising increase in IL-2 secretion after B7 or anti-CD28 stimulation. The effect of wortmannin was concentration dependent. Moreover, the effect was specific for receptor-mediated activation as wortmannin did not enhance phorbol ester plus ionomycin-induced IL-2 secretion. Another inhibitor of PI 3-kinase, LY294002, also resulted in augmentation of anti-CD28-induced IL-2 secretion by Jurkat cells. The effects of wortmannin on IL-2 secretion were also examined in primary T cells. In marked contrast, wortmannin resulted in a potent inhibition of anti-CD3 plus B7-1 or anti-CD28-induced IL-2 secretion while phorbol ester plus ionomycin-induced IL-2 secretion was wortmannin resistant. Together these observations demonstrate that signal transduction by both B7-1 and B7-2 involves PI 3-kinase, and that PI 3-kinase or other wortmannin-sensitive targets are important for IL-2 secretion. Finally, treatment of Jurkat cells with PI 3-kinase inhibitors alone was sufficient to induce low levels of IL-2 secretion. This is consistent with the notion that a wortmannin-sensitive target such as PI 3-kinase may down-regulate IL-2 secretion in Jurkat cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7577804     DOI: 10.1093/intimm/7.6.957

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  17 in total

1.  A human class II MHC-derived peptide antagonizes phosphatidylinositol 3-kinase to block IL-2 signaling.

Authors:  M L Boytim; P Lilly; K Drouvalakis; S C Lyu; R Jung; A M Krensky; C Clayberger
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

2.  Autophosphorylation of p110delta phosphoinositide 3-kinase: a new paradigm for the regulation of lipid kinases in vitro and in vivo.

Authors:  B Vanhaesebroeck; K Higashi; C Raven; M Welham; S Anderson; P Brennan; S G Ward; M D Waterfield
Journal:  EMBO J       Date:  1999-03-01       Impact factor: 11.598

3.  Lack of costimulation by both sphingomyelinase and C2 ceramide in resting human T cells.

Authors:  D O'Byrne; D Sansom
Journal:  Immunology       Date:  2000-06       Impact factor: 7.397

Review 4.  T cell signal transduction and the role of CD7 in costimulation.

Authors:  R Stillwell; B E Bierer
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

5.  OX40 complexes with phosphoinositide 3-kinase and protein kinase B (PKB) to augment TCR-dependent PKB signaling.

Authors:  Takanori So; Heonsik Choi; Michael Croft
Journal:  J Immunol       Date:  2011-02-02       Impact factor: 5.422

Review 6.  CD28/B7 regulation of autoimmune diabetes.

Authors:  K G Herold; D J Lenschow; J A Bluestone
Journal:  Immunol Res       Date:  1997-02       Impact factor: 2.829

7.  Stimulation of a shorter duration in the state of anergy by an invariant natural killer T cell agonist enhances its efficiency of protection from type 1 diabetes.

Authors:  R Tohn; H Blumenfeld; S M M Haeryfar; N Veerapen; G S Besra; S A Porcelli; T L Delovitch
Journal:  Clin Exp Immunol       Date:  2011-03-01       Impact factor: 4.330

8.  Akt2 inhibits the activation of NFAT in lymphocytes by modulating calcium release from intracellular stores.

Authors:  Victoria A Martin; Wen-Horng Wang; Andrew M Lipchik; Laurie L Parker; Yantao He; Sheng Zhang; Zhong-Yin Zhang; Robert L Geahlen
Journal:  Cell Signal       Date:  2012-01-11       Impact factor: 4.315

9.  The adaptor molecule MyD88 activates PI-3 kinase signaling in CD4+ T cells and enables CpG oligodeoxynucleotide-mediated costimulation.

Authors:  Andrew E Gelman; David F LaRosa; Jidong Zhang; Patrick T Walsh; Yongwon Choi; J Oriol Sunyer; Laurence A Turka
Journal:  Immunity       Date:  2006-10-19       Impact factor: 31.745

10.  CD86 gene variants and susceptibility to pancreatic cancer.

Authors:  Honggang Xiang; Wei Zhao; Yanping Sun; Winnie Qian; Junjie Xing; Yujia Zhou; Jun Yao; Jian Xu; Yi Wang; Houshan Yao; Zhiqian Hu
Journal:  J Cancer Res Clin Oncol       Date:  2012-07-21       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.